Sutro Biopharma, Inc. · NASDAQ:STRO

Sutro Biopharma — Investor Presentation (November 2026)

32 slides from Sutro Biopharma's investor presentation, November 2026

  1. Slide 1: Designed to Deliver

    DESIGNED / / TO DELIVER November 2026

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state

  3. Slide 3: Differentiated Pipeline of Single- and Dual-Payload ADCs

    Differentiated Pipeline of Single- and Dual-Payload ADCs SINGLE-PAYLOAD ADCs: DUAL-PAYLOAD ADCs: Focused on Complex Targets Overcome Resistance and Expressed Across Many Tumor Types Delay Progression STRO-004: STRO-006: TF-Targeting ADC ITGβ6-Targeting ADC​ STRO-227: PTK7-Targeting dpADC Best-in-cla

  4. Slide 4: Next-Generation ADCs Enabled by Sutro's Proprietary Platform

    Next-Generation ADCs Enabled by Sutro’s Proprietary Platform

  5. Slide 5: Sutro's Proprietary Cell-Free Platform Designed to Optimize Every Component of the ADC

    Sutro’s Proprietary Cell-Free Platform Designed to Optimize Every Component of the ADC Expanding the therapeutic window to minimize toxicity and maximize efficacy DESIGN FEATURES ADVANTAGES 1 ANTIBODY ▸ Design antibodies for better tumor affinity, 1 ▸ High-throughput capabilities identify avoiding i

  6. Slide 6: Our Proprietary Platform Enables Industry-Leading ADC Exposure

    Our Proprietary Platform Enables Industry-Leading ADC Exposure, a Key Driver of Safety and Efficacy Comparing ADC Exposure in NHPs at DAR16 ADCs Highest Non-Severely Toxic Dose 6,000 Total Ab (ng/mL) Site combo A Conjugated PL Exposure [h ug/mL] 100,000 Site combo B 5,000 Site combo C STRO-ADC DAR8

  7. Slide 7: STRO-004

    STRO-004 Potential Best-in-Class Exatecan ADC Targeting Tissue Factor

  8. Slide 8: STRO-004: Next Generation TF-Targeting Exatecan ADC Engineered for Enhanced Therapeutic Index

    STRO-004: Next Generation TF-Targeting Exatecan ADC Engineered for Enhanced Therapeutic Index 50x preclinical exposure vs approved TF ADC 1 1 ANTIBODY ▸Tumor targeting, does not interfere with TF biology ▸Fc-silent to reduce ILD risk 2 PAYLOAD ▸DAR8; safely boosts potency ▸Drives efficacy in low-cop

  9. Slide 9: Significant Unmet Need Across Large Oncology Patient Populations

    Significant Unmet Need Across Large Oncology Patient Populations Incidence (U.S.) and relapsed/refractory ORR and OS benchmarks across select relevant tumor types Incidence (U.S.) and Relapsed/Refractory ORR and TF Current Std of Care in R/R OS Benchmarks Across Select Relevant Tumor Types Expressio

  10. Slide 10: STRO-004 Detailed Monotherapy Development Strategy: Phase 1 STRIVE Trial Ongoing

    STRO-004 Detailed Monotherapy Development Strategy: Phase 1 STRIVE Trial Ongoing Next data update planned for 1H 2027 Move Forward with Tumor type eligibility Dose Escalation Recommended Dose(s) based on prevalence of TF expression: • Detection of activity Dose Level 5 mg/kg • Characterization of sa

  11. Slide 11: STRO-004 Phase 1: Encouraging Early Clinical Activity with Favorable Tolerability & PK

    STRO-004 Phase 1: Encouraging Early Clinical Activity with Favorable Tolerability & PK Clinical Activity Tolerability & PK Multiple Responses Favorable Across Doses Confirmed + ongoing unconfirmed PRs at 3–4 mg/kg 1–5 mg/kg, n=49 ▸Confirmed and ongoing unconfirmed responses in PDAC, HNSCC ▸Mostly lo

  12. Slide 12: STRO-004 Dose-Proportional PK: Cell-Free Technology Enables Wider TI

    STRO-004 Dose-Proportional PK: Cell-Free Technology Enables Wider TI with Less Platform Toxicity Long half-life of nearly 7 days, maintains 98% DAR8 configuration Highly Stable ADC: High Drug Exposure and Low Levels of Free Payload (below 10 ng/mL) Across Doses Free payload below red zone supports l

  13. Slide 13: STRO-004 Favorable Tolerability Profile: Mostly Low-Grade AEs

    STRO-004 Favorable Tolerability Profile: Mostly Low-Grade AEs with Limited On-Target and Platform Tox All-grade TRAEs ≥10% of Subjects and All Gr 3+ Events; Low Discontinuation Rate Due to AEs of 6% Dose Level (n) 1 mg/kg (2) 2 mg/kg (10) 3 mg/kg (13) 4 mg/kg (16) 5 mg/kg (8) Overall (49) ▸All-grade

  14. Slide 14: STRO-006

    STRO-006 Potential Best-in-Class Exatecan ADC Targeting Integrin-Beta 6

  15. Slide 15: STRO-006: Next-Generation ITGβ6-Targeting Exatecan ADC

    STRO-006: Next-Generation ITGβ6-Targeting Exatecan ADC Engineered for Selectivity and Tolerability STRO-006 has superior preclinical activity vs clinical benchmark 1 1 ANTIBODY ▸High affinity to ITGβ6 without effect on TGFβ signaling ▸Fc-silent to reduce ILD risk 2 PAYLOAD ▸ Highly stable DAR8 ▸ Pot

  16. Slide 16: ITGβ6 Expression has Unique Promise in NSCLC and Other Solid Tumors

    ITGβ6 Expression has Unique Promise in NSCLC as well as Other Common Solid Tumors STRO-006 is designed for monotherapy and combination use, expanding its therapeutic reach Incidence (U.S.) and Relapsed/Refractory ORR and ITGβ6 Current Std of Care in R/R OS Benchmarks Across Select Relevant Tumor Typ

  17. Slide 17: STRO-006 Has Shown Superior Activity vs Competitor ADCs in CDX Models

    STRO-006 Has Shown Superior Activity at Relevant Doses to Competitor ADCs in CDX Preclinical Models Expressing ITGβ6 Head and Neck (ITGβ6+) Lung (ITGβ6+) Bladder (ITGβ6+) CDX – Cell-line derived xenograft; DAR – Drug to antibody ratio; ITGB6 – Integrin beta-6; MMAE – Monomethyl Auristatin E (tubulin

  18. Slide 18: STRO-006 Responses are Durable Across PDX Models of HNSCC and NSCLC

    STRO-006 Responses are Durable Across PDX Models of HNSCC and NSCLC Following a Single Clinically Relevant Dose​ HNSCC ad.NSCLC sq.NSCLC ORR 15/21 14/19 14/18 PDX – Patient-derived xenograft; HNSCC – Head and neck squamous cell carcinoma; NSCLC – Non-small cell lung cancer; sq. – Squamous Cell Carci

  19. Slide 19: STRO-006 Improved PFS in Non-Squamous and Squamous PDX Models of NSCLC

    STRO-006 Improved PFS in Both Non-Squamous and Squamous PDX Models of NSCLC PDX – Patient-derived xenograft; NSCLC – Non-small cell lung cancer; sq. – Squamous Cell Carcinoma; ad. – adenocarcinoma; ORR – Overall response rate; PFS – Progression-free survival NON-CONFIDENTIAL 19

  20. Slide 20: STRO-006 Phase 1 Designed to Rapidly Reach Therapeutic Doses

    STRO-006 Phase 1 Designed to Rapidly Reach Therapeutic Doses Entered the clinic 3Q 2026; Initial clinical data expected in 2H 2027 Dose Escalation Move Forward with Advanced Solid Tumors with ITGB6 Expression Recommended Dose(s) Tumor type eligibility selected for ITGB6 • Detection of activity expre

  21. Slide 21: Delivering Dual Payloads: The Next Revolution in ADCs

    Delivering Dual Payloads: The Next Revolution in ADCs

  22. Slide 22: Dual-Payload ADCs: Targeted Combination Therapy to Improve Outcomes

    Dual-Payload ADCs: Targeted Combination Therapy to Improve Outcomes Combination treatment approaches have been shown to improve outcomes in oncology versus single-agent chemotherapy and remain standard of care in many therapeutic areas Dual-Payload ADCs: Potential to Become Future Standard of Care •

  23. Slide 23: Proprietary Cell-Free Platform Positions Sutro at the Forefront of Dual-Payload Innovation

    Proprietary Cell-Free Platform Positions Sutro at the Forefront of Dual-Payload Innovation Topo1 x Tubulin Enables novel drug combinations and tuning of ratios with Multiple Modalities Topo1 x DDRi the broadest payload diversity to overcome tumor resistance and improve tolerability Topo1 x IO Tailor

  24. Slide 24: Sutro's First Wholly-Owned Dual-Payload ADC Targeting PTK7

    Sutro’s First Wholly-Owned Dual-Payload ADC Targeting PTK7 A clinically validated, pan-tumor target enriched on tumor-initiating cells • Broad expression across high-need indications and Breast Cancer Xenograft Model​ associated with poor prognosis • Anti-tumor clinical activity of an anti-PTK7 ADC

  25. Slide 25: Broad Anti-Tumor Activity of STRO-227 Across PDX Models

    Broad Anti-Tumor Activity of STRO-227 Across PDX Models STRO-227 achieves deeper responses Vehicle TNBC PDX Ovarian PDX Trop2 DAR4-DXd, 5 mg/kg than single-payload benchmarks in Dose-dependent anti-tumor activity in TNBC and Ovarian PDX models ITGB6 DAR4-MMAE, 5 mg/kg selected NSCLC PDX models STRO-

  26. Slide 26: STRO-227 Drives Regressions in PDX Models After Progression on Single-Payload ADCs

    STRO-227 Drives Regressions in PDX Models Derived After Clinical Progression on Single-Payload ADCs Ovarian Cancer PDX TNBC PDX Patient Progressed on an MTI ADC Patient Progressed on a Topo1i ADC Vehicle Vehicle Elahere clinical grade, 5 mg/kg Dato-DXd clinical grade, 5 mg/kg STRO-227, 5 mg/kg STRO-

  27. Slide 27: Sutro Dual-Payload ADC: Preclinical Tolerability Meets Single-Payload Benchmarks

    Sutro Dual-Payload ADC: Preclinical Tolerability Meets Single- Payload Benchmarks Even with Added MMAE Payload Area Target Linker Payload DAR NHP HNSTD Highest Clinical Phase Exatecan + 25 mg/kg STRO-227 PTK7 β-Glu 8+2 Preclinical MMAE (Q3Wx2) Enhertu HER-2 GGFG Deruxtecan 8 30 mg/kga (Q3Wx3) Approv

  28. Slide 28: Dual-Payload ADCs Demonstrated Greater Anti-Tumor Activity than Co-Administered Single-Payload ADC

    Sutro’s Dual-Payload ADCs Demonstrated Greater Anti-Tumor Activity than Co-Administered Single-Payload ADC Enhertu-Resistant Ovarian Adenocarcinoma Model Event-Free Survival Sutro’s dpADC Vehicle Total aHER2 DAR8 Exatecan Group Dose Dose aHER2 DAR4 MTi Co-Administration --- --- Vehicle DAR8+4 dpADC

  29. Slide 29: Dual-Payload ADCs Have Overcome Resistance and Driven Tumor Regression

    Dual-Payload ADCs Have Overcome Resistance and Driven Tumor Regression in Preclinical Models Dual-Payload ADC Induced Tumor Dual-Payload ADCs Have Improved In Vivo Regression After Sequential ADC Resistance Efficacy in an MTi-Resistant CRC Xenograft Model HCT-116 Tumor Growth Curves 10 mg/kg Enhertu

  30. Slide 30: iADC: Dual-Payload ADC Combining Cytotoxin and Immune Stimulator

    iADC: Dual-Payload ADC Combining Tumor-Targeted Delivery of a Cytotoxin and Immune Stimulator Strategic partnership with Astellas to deliver new treatment options for cold tumors and patients unresponsive to existing cancer immunotherapies Combining a cytotoxin and immune modulator gives potential t

  31. Slide 31: Pipeline of Next-Generation Single- and Dual-Payload ADCs

    Pipeline of Next-Generation Single- and Dual-Payload ADCs On track to deliver three wholly-owned programs into the clinic in two years PHASE 3/ PROGRAM MODALITY/TARGET INDICATION DISCOVERY PRECLINICAL PHASE 1/1B PHASE 2 REGISTRATIONAL PARTNER STRO-004 Tissue Factor ADC Solid Tumors ONCOLOGY PROGRAMS

  32. Slide 32: Recent Achievements and Upcoming Milestones

    Recent Achievements and Upcoming Milestones Targeted Timing STRO-004, Tissue Factor (TF)-targeting DAR8 exatecan ADC Report initial safety, PK and early clinical activity from dose escalation (1–5 mg/kg, n=49) Aug 2026 Complete dose optimization and provide next STRIVE-01 study update 1H 2027 Initia

Sutro Biopharma — Investor Presentation (November 2026) on 6ix